Clinical Trial

Phase I Study of QLS1510 Tablets in Healthy Participants

Name: Phase I Study of QLS1510 Tablets in Healthy Participants — clinical trial record (NCT07760077)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QLS1510 in Healthy participants

Trial Details

NCT Number	NCT07760077
Lead Sponsor	Shanghai Qilu Pharmaceutical Research and Development Center LTD
Conditions	Inflammatory Bowel Disease (IBD)
Enrollment	90 participants
Start Date	2026-08-30
Primary Completion	2027-01-30 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-12